INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
1 .- 20 . (canceled)
21 . A method of treating a patient diagnosed with a form of cancer characterized by an IDH1 mutation selected from the group consisting of R132G, R132S and R132L, the method, comprising administering to the subject 300 mg of Compound 1
per day.
22 . The method of claim 21 , wherein the patient is diagnosed with a cancer characterized by a concurrent mutation selected from the group consisting of FLT3, NPM1, CEBPA and TP53.
23 . The method of claim 21 , wherein the patient is diagnosed with a cancer that is not characterized by an IDH2 mutation.
24 . The method of claim 21 , wherein the patient is diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) characterized by the IDH1 mutation.
25 . The method of claim 24 , wherein the patient is diagnosed with MDS or AML further characterized by a concurrent mutation selected from the group consisting of FLT3, NPM1, CEBPA and TP53.
26 . The method of claim 21 , wherein the patient is diagnosed with a cancer characterized by a concurrent mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, FLT3, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53.
27 . A method of treating a patient diagnosed with a hematological malignancy characterized by an IDH1 mutation selected from the group consisting of R132C, R123H, R132G, R132S and R132L and a concurrent FLT3 mutation, the method comprising administering a total of 150 mg of Compound 1 orally twice per day (e.g. only twice per day) to the patient in need thereof:
28 . The method of claim 27 , wherein the patient is diagnosed with a hematological malignancy characterized by a co-mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53.
29 . The method of claim 27 , comprising administering Compound 1 to the patient every day for 6 months.
30 . The method of claim 27 , wherein Compound 1 is administered to the patient as a single agent for the treatment of AML.
31 . The method of claim 27 , wherein Compound 1 is administered to the patient in combination with azacitidine during one or more 28-day treatment cycles, wherein
a. the azacitidine is administered to the patient at the dose of 75 mg/m 2 for 7 days IV/SC per every 28-day cycle; and
b. a total of 150 mg of Compound 1 is administered to the patient twice per day throughout the 28-day treatment cycles.
32 . The method of claim 27 , wherein the patient does not have an IDH-2 mutation.
33 . A method of treating a patient diagnosed with a form of cancer characterized by an IDH1 mutation selected from the group consisting of R132G, R132S and R132L, the method comprising orally administering to the patient in need thereof a total amount of 150 mg of Compound 1 BID to the patient in need thereof:
each day for a total of at least 6 months to treat the cancer characterized by the IDH1 mutation.
34 . The method of claim 33 , wherein the patient is diagnosed with a cancer characterized by a concurrent FLT3 mutation.
35 . The method of claim 33 , wherein the patient is diagnosed with a cancer characterized by a concurrent NPM1 mutation.
36 . The method of claim 33 , wherein the patient is diagnosed with a cancer characterized by a concurrent CEBPA mutation.
37 . The method of claim 33 , wherein the patient is diagnosed with a cancer characterized by a concurrent TP53 mutation.
38 . The method of claim 33 , wherein the patient is diagnosed with a cancer further characterized by both the mIDH1 mutation and a co-mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53.
39 . The method of claim 34 , wherein Compound 1 is administered as a single agent without azacitidine.
40 . The method of claim 34 , wherein Compound 1 is administered in combination with azacitidine to treat the mIDH1 cancer.